The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company ...

W ASHINGTON — Two powerful House Democrats on Monday demanded documents from Biogen about the approval process, marketing, and pricing of its controversial new Alzheimer’s drug.

Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.

WASHINGTON, February 5, 2021 /CSRwire/ - Arcadia, a monthly subscription service that connects renters and homeowners across the US to wind and solar energy through their utility accounts, today ...

Biogen Puts $250 Million Toward Goal Of Going Fossil Fuel-Free By 2040. September 14, 2020. ... Murphy says the initiative will go beyond supplying green energy to Biogen's facilities, ...

Biogen. Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the ...

Aduhelm was surrounded by controversies since the U.S. FDA approved it for the treatment for Alzheimer's in June last year. It was the first drug to be approved in 18 years for the disease.

Two high-ranking Congressional Democrats are pushing Biogen to answer for a slew of concerns over its hotly contested Alzheimer’s treatment Aduhelm, including reports of the drugmaker’s cozy ...

WASHINGTON, Feb. 5, 2021 /PRNewswire/ -- Arcadia, a monthly subscription service that connects renters and homeowners across the US to wind and solar energy through their utility accounts, today ...